Tofacitinib vs TNF inhibitors in #RA patients +50yrs with >1 CV risk factor; the data from ORAL Surveillance that we have all been waiting for! #ACR21 Risk of MACE related largely to baseline CV risk https://t.co/SpuKTtP8ql